Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02334267 · ClinicalTrials.gov registry record · NA
Acid-Base Composition With Use of hemoDialysates
A NA study of End Stage Renal Disease, sponsored by Fresenius Medical Care North America.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT02334267: Completed NA study of End Stage Renal Disease, sponsored by Fresenius Medical Care North America.
NCT02334267 is a NA study of End Stage Renal Disease that has completed, run by Fresenius Medical Care North America. The registered enrollment target is 11 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02334267, a NA study of End Stage Renal Disease, has completed, sponsored by Fresenius Medical Care North America.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a prospective, single center, single blind (patient and laboratory), randomized, cross-over, two week investigation of intradialytic acid-base kinetics and physiology associated with use of two commercial acid dialysate concentrates in prevalent hemodialysis patients.
Primary Outcome
Quantification of Peridialytic Arterialized Blood Bicarbonate Concentrations
Conditions Studied
Interventions
- DEVICE Group 1: GranuFlo
- DEVICE Group 2: NaturaLyte
Study Locations (1)
Tennessee
- Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-09 |
| Phase | NA |
What the finished NCT02334267 record still lists
NCT02334267 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 2 interventions - of which Group 1: GranuFlo is the first listed.
NCT02334267 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT02334267 about?
NCT02334267 is a clinical study titled "Acid-Base Composition With Use of hemoDialysates". This study is a prospective, single center, single blind (patient and laboratory), randomized, cross-over, two week investigation of intradialytic acid-base kinetics and physiology associated with use of two commercial acid dialysate concentrates in prevalent hemodialysis patients.
What is the current status of trial NCT02334267?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2014-11. Estimated completion is 2015-09.
What conditions does trial NCT02334267 study?
This clinical trial studies the following conditions: End Stage Renal Disease.
What interventions are being tested in trial NCT02334267?
The interventions under investigation include: Group 1: GranuFlo (DEVICE), Group 2: NaturaLyte (DEVICE).
Who is sponsoring clinical trial NCT02334267?
This trial is sponsored by Fresenius Medical Care North America, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02334267 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02334267's enrollment target sits among peer trials
11 78th of 86 higher than 8 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
-
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
RECRUITING · NA
-
CAPABLE Transplant
RECRUITING · NA
-
Intravascular Ultrasound in Patients With End-stage Renal Disease on Dialysis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia